Evidence map›Paper›PMID 26464711›Full record

ArticleInternational journal of clinical and experimental pathology2015

Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer.

Yonghui Zhang, Bin Zhang, Jing Fang, Xuchen Cao

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yonghui ZhangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin, China ; Key Laboratory of Cancer Prevention and Therapy Tianjin, China ; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education Tianjin 300060, China ; Department of Oncologic Surgery, Weinan Center Hospital Weinan 714000, Shaanxi, China.
Bin ZhangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin, China ; Key Laboratory of Cancer Prevention and Therapy Tianjin, China ; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education Tianjin 300060, China.
Jing FangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin, China ; Key Laboratory of Cancer Prevention and Therapy Tianjin, China ; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education Tianjin 300060, China.
Xuchen CaoTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin, China ; Key Laboratory of Cancer Prevention and Therapy Tianjin, China ; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education Tianjin 300060, China.
Tianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the methylation status of DNA-binding inhibitor 4 (ID4) in tamoxifen-refractory (TR) breast cancer.

methodsFrom January 2012 to December 2014, breast cancer patients managed by radical mastectomy previously and receiving tamoxifen treatment for at least 12 months were enrolled. According to the response to tamoxifen, patients were divided into TR group and tamoxifen-sensitive (TS) group. Genomic DNA was isolated from fasting venous blood, and methylight technique was applied to determine the methylation status of ID4.

results43 patients with TS breast cancer and 31 patients with TR breast cancer were enrolled. No significant difference between groups was observed in term of patients' characteristics, such as age (P=0.693), progesterone receptor (P=0.970), menopausal status (P=0.784) and histological type (P=0.537), while the stage of cancer in TR group was significantly higher than TS group (P<0.001). Compared to TS group, PMR of ID4 was significantly higher in TR group (P=0.002). ROC curve analysis indicated that ID4 yielded an AUC of 0.716 with 77.4% sensitivity and 62.79% specificity in distinguishing TR breast cancer at the cut point of 3.8%. The PMR cut point of ID4 was set at 6.8% in survival analysis, log-rank test indicated the risk of disease progression was comparable between patients with ID4 hypermethylation or hypomethylation (P=0.287).

conclusionID4 hypomethylation is present in TR breast cancer, and it may serve as a potential biomarker in distinguishing TR breast cancer. However, the results need further validation in larger studies.

Indexed as

DNA MethylationAdultAntineoplastic Agents, HormonalBreastBreast NeoplasmsDiagnosis, DifferentialFemaleHumansInhibitor of Differentiation ProteinsMiddle AgedTamoxifenAntineoplastic Agents, HormonalID4 protein, humanInhibitor of Differentiation ProteinsTamoxifenbreast cancerDNA-binding inhibitor 4mastectomymethylightsurvival analysistamoxifen

Identifiers

PMID26464711
PMCPMC4583943
OpenAlexW2418226578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.